Related Experiment Video
Updated: Dec 25, 2025
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Current Advances in Pediatric Onset Multiple Sclerosis
Kristen S Fisher1, Fernando X Cuascut2, Victor M Rivera2
1Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA.
Insights
Pediatric multiple sclerosis (MS) diagnosis and treatment have advanced, with earlier interventions and higher-efficacy therapies now standard for managing this rare central nervous system disease in children.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- Multiple sclerosis (MS) is a rare autoimmune inflammatory central nervous system disease causing demyelination.
- Pediatric MS can lead to significant long-term disability.
- Advances in diagnosis and treatment are crucial for managing pediatric MS.
Purpose of the Study:
- To review current knowledge on the diagnosis of pediatric MS.
- To discuss contemporary treatment strategies, including disease-modifying therapies (DMTs).
- To examine clinical outcomes in children and adolescents with MS.
Main Methods:
- Literature review of recent studies on pediatric MS.
- Analysis of diagnostic criteria evolution.
- Evaluation of treatment trends and efficacy of DMTs.
Main Results:
- Improved diagnostic criteria enable earlier MS diagnosis in pediatric patients.
- Treatment patterns have shifted towards earlier initiation of high-efficacy DMTs.
- Evidence supports using more potent therapies to prevent disease progression.
Conclusions:
- Earlier diagnosis and treatment initiation are key in pediatric MS management.
- High-efficacy DMTs are increasingly used at diagnosis to mitigate disability.
- Ongoing research is vital for optimizing long-term outcomes in pediatric MS.
Abstract:
Multiple sclerosis (MS) is an autoimmune inflammatory disease affecting the central nervous system leading to demyelination. MS in the pediatric population is rare, but has been shown to lead to significant disability over the duration of the disease. As we have learned more about pediatric MS, there has been a development of improved diagnostic criteria leading to earlier diagnosis, earlier initiation of disease-modifying therapies (DMT), and an increasing number of DMT used in the treatment of pediatric MS. Over time, treatment with DMT has trended towards the initiation of higher efficacy treatment at time of diagnosis to help prevent further disease progression and accrual of disability over time, and there is evidence in current literature that supports this change in treatment patterns. In this review, we discuss the current knowledge in diagnosis, treatment, and clinical outcomes in pediatric MS.
More Related Videos
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:15Parkinson's Disease: Overview
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...